Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Part 2
Through this agreement, Apicell Therapeutics expects to revitalize researcher-led clinical linkage research in the field of gene-transduced mesenchymal stem cell therapy. In addition, it is expected that it will be an opportunity to accelerate the development of cell gene therapy and solidify the foundation of the R&D system by jointly carrying out national tasks with Samsung Seoul Hospital.
Jong-sang Yoo, CEO of Apicell Therapeutics, said, “I am delighted to be conducting this joint research with the Cell and Gene Therapy Research Center at Samsung Seoul Hospital, which is composed of top-notch medical staff and has a lot of research experience. We will strengthen research cooperation to open a new path for the development of cell and gene therapeutics for diseases.”
Part 1 of translation
Apicell Therapeutics (CEO Jeon Seung-ho, Yoo Jong-sang), a joint venture between Daewoong Pharmaceutical and British Avacta, signed an MOU for joint research cooperation with Samsung Seoul Hospital (President Park Seung-woo) for ‘innovative research and development in the field of cell and gene therapy’. ) was signed on the 31st.
The MOU ceremony was held at the Ilwon Station campus of Samsung Medical Center, including Jong-Sang Yoo, CEO of Apicell Therapeutics, Ki-Nam Kim, Head of Strategic Planning Office, Kyung-Hoon Ahn, Head of Strategic Planning Office, Seung-Hyeon Choi, Senior Researcher Kyu-Sung Lee, Vice President of Research and Future Medicine Research Institute at Samsung Seoul Hospital, and Yoon-Sil Jang, Cell and Gene Therapy Researcher Director, Lee Ji-hoon, director of the Gene Therapy Research Center, and Jang Jong-wook, head of the GMP cell production team, attended and exchanged agreements.
Through this MOU, the two companies plan to cooperate with each other, including ?exchanging trends and technical information in the field of gene-introduced mesenchymal stem cell therapy ? conducting joint research on national projects related to cell and gene therapy development.
UK life science company Avacta is closing its therapeutics facility in Cambridge and will now house all relevant staff under one roof in London.
The company declined to say how many staff were employed at Cambridge or how many had agreed to transfer to the new therapeutics HQ at Scale Space in Imperial College’s White City Campus. Previously the therapeutics Research & Development teams were split between Cambridge and London.
A spokesperson told Business Weekly that the new site was “better equipped to serve the development of both Avacta and its people – the key benefits behind the decision being that the site is larger and houses more modern facilities.”
The AIM-listed group is nevertheless going against the flow of traffic. It moves out of Cambridge, one of the world’s most prestigious life science clusters, just as record numbers based here expand facilities and newcomers flow in.
Avacta said the new therapeutics HQ – it runs diagnostics from separate facilities – is designed to support the continued growth of the company’s pre-clinical and clinical development pipelines of innovative cancer therapies.
The move follows the transition of AVA6000, the lead pre|CISIONTM targeted chemotherapy programme and a tumour activated form of doxorubicin, into the clinic in August 2021.
Dr Fiona McLaughlin, chief scientific officer at Avacta, said: “This move is the result of a clear vision to bring together the research and development teams into one hub to facilitate the translation of our in-house research from bench to bedside.
“We are now at the heart of the innovative White City community in London, readily accessible to our collaborators around the world and poised to take Avacta to the next level in its evolution as a clinical stage biopharmaceutical company.”
https://www.businessweekly.co.uk/news/biomedtech/avacta-therapeutics-arm-quits-cambridge
Abstract
Having varied approaches to the design and manufacture of vaccines is critical in being able to respond to worldwide needs and to newly emerging pathogens. Virus-like particle (VLP) vaccines form the basis of two of the most successful licensed vaccines (against hepatitis B virus (HBV) and human papillomavirus). They are produced by recombinant expression of viral structural proteins, which self-assemble into immunogenic nanoparticles. VLPs can also be modified to present unrelated antigens, and here we describe a universal bolt-on vaccine platform (termed VelcroVax) where the capturing VLP and the target antigen (hapten) are produced separately. We utilise a modified HBV core (HBcAg) VLP, with surface expression of a high-affinity binding sequence (Affimer) directed against a SUMO tag and use this to capture SUMO-tagged gp1 glycoprotein from the arenavirus, Junin virus (JUNV). Using this model system, we have solved high-resolution structures of VelcroVax VLPs, and shown that the VelcroVax-JUNV gp1 complex induces superior humoral immune responses compared to the non-complexed viral protein. We propose that this system could be modified to present a range of haptens and therefore form the foundation of future rapid-response vaccination strategies.
https://www.biorxiv.org/content/10.1101/2022.04.22.489148v1
One in ten people may still be infectious for Covid after ten days, study finds
https://www.dailymail.co.uk/news/article-10399167/One-ten-people-infectious-Covid-ten-days-study-finds.html
The whole world (apart from China) need lateral flow Tests....when we finally get the needed authorisation they will sell all they can make.
That's alot of people !
Sound familiar ???
Scott Morrison has defended the government's supply of Covid-19 rapid antigen tests, saying the whole world has been under pressure from the Omicron variant and scrapping for test supplies.
https://www.dailymail.co.uk/news/article-10373625/Scott-Morrison-defends-nationwide-shortage-rapid-antigen-tests-amid-Omicron-chaos.html
SAGE member John Edmunds, a modeller at the London School of Hygiene & Tropical Medicine, said: 'This change makes a lot of sense.
'When the prevalence is high — and it is incredibly high at the moment — almost everyone who tests positive with a lateral flow test will be a true positive.
'There is really no need to confirm this with a PCR, a step that not only wastes time but costs a lot of money and uses up laboratory resources that could be better used elsewhere. There are down sides to this change.
'We would have slightly less information on the relative prevalence of the different variants circulating in the community, as PCR swabs undergo genotyping and sequencing, and the daily number of confirmed cases may need more careful interpretation.
'Overall, though, I think that these downsides are worth it.'
Sir David Spiegelhalter, chair of the Winton Centre for Risk and Evidence Communication at the University of Cambridge, said: 'This seems a sensible move.
'We argued back in October that it seemed fairly pointless to do a confirmatory PCR after a positive lateral flow test.
'This is even more true now: with current infection rates, a positive LFD followed by a negative PCR would still mean it was very likely that you were carrying the virus.
https://www.dailymail.co.uk/news/article-10371411/Asymptomatic-people-England-wont-need-confirmatory-PCR-January-11-health-chiefs-confirm.html
Mustang74 - USA don't think it's over. ..
Biden signs $137 million deal with German pharmaceutical company for COVID test strip factory that will take THREE YEARS to build and will start producing 83.3 million tests a month in late 2024 at the earliest
https://www.dailymail.co.uk/news/article-10355941/Biden-signs-137M-deal-COVID-test-factory-start-producing-83-3M-tests-month-late-2024.html
Muck165 - this is from RNS in November.(suspended further sales)
1 November 2021, the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA regulations”) have come into force. Consistent with these new regulations the Company has suspended, as of 1 November 2021, further sales of its AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test in the UK until the ongoing desktop evaluation of the test has been successfully completed by the Agency and the test subsequently is put on the CTDA register for approved products.
Wife picked up a box of tests today as she is NHS staff....Healgen (Chinese )
Lateral flow tests are set to be in short supply for another two weeks as officials grapple with 'huge demand', Sajid Javid has admitted
In a letter to MPs, he said: "In light of the huge demand for LFDs seen over the last three weeks, we expect to need to constrain the system at certain points over the next two weeks to manage supply over the course of each day, with new tranches of supply released regularly throughout each day."
He went on to promise that capacity would be ramped up in the New Year, with the government buying millions more lateral flow tests, bringing in new products and accelerating deployment to the public.
"We are also doubling our total delivery capacity with Royal Mail to 900,000 test packs and PCR tests a day. We are tripling the supply of LFDs in January and February from our pre-Omicron plan of 100 million to 300 million per month," he added.
https://news.sky.com/story/covid-19-great-concern-amid-shortage-of-coronavirus-tests-before-new-years-eve-parties-as-system-may-need-to-be-constrained-further-12506244
It's mind blowing that the so called expert's are only just coming to the conclusion that LFTs are the way to keeping the world's health and economy moving forward.